The DELIVER trial demonstrated that dapagliflozin decreased the risk of worsening heart failure or cardiovascular death among patients with HFpEF. The EMPEROR-PRESERVED trial demonstrated significant reductions in cardiovascular mortality, heart failure-related…
— EchoTalk Echocardiography (@echotalk) June 21, 2024
